Replimune Group Inc REPL

Healthcare Biotechnology

Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. It is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.

NDAQ:REPL - Post by User

Replimune Group Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Jun 07, 2024 1:15pm

37 Views

Post# 36077966

Replimune to Present at the Goldman Sachs 45th Annual Global

News; $REPL Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference | BenzingaWOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the deve...REPL - Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference | Benzinga

<< Previous

Bullboard Posts

Next >>

Gold, growth and sustainability in focus for Mandalay Resources